

Cover Story
Relying largely on maturing data from the European trials of screening for prostate cancer, the U.S. Preventive Services Task Force has given a better grade—a “C”—to screening for prostate cancer.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- Trump executive order to “Make America Healthy Again” cites questionable data from Wuhan
White House cites paper in pay-to-play journal claiming that U.S. has highest age-standardized incidence rate of cancer - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Fired NCI employee says Trump’s purge was baseless yet punitive
“I feel like I’ve been erased” - As cancer research is threatened, we must engage in political advocacy
- “The Agency finds you are not fit…”
HHS notifications of firing add insult to injury - Pushing for tax cuts, Trump threatens the federal workforce, Medicaid, and cancer research